Premium
Graphene Oxide/Ag Nanoparticles Cooperated with Simvastatin as a High Sensitive X‐Ray Computed Tomography Imaging Agent for Diagnosis of Renal Dysfunctions
Author(s) -
Li Zhan,
Tian Longlong,
Liu Jianli,
Qi Wei,
Wu Qiang,
Wang Haijing,
Ali Mohammad Chand,
Wu Wangsuo,
Qiu Hongdeng
Publication year - 2017
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201700413
Subject(s) - simvastatin , graphene , in vivo , materials science , biomedical engineering , medicine , nanotechnology , radiology , pharmacology , microbiology and biotechnology , biology
Graphene oxides (GO) are attracting much attention in the diagnosis and therapy of the subcutaneous tumor as a novel biomaterial, but its diagnosis to tissue dysfunction is yet to be found. Here, a novel application of GO for diagnosis of renal dysfunction via contrast‐enhanced computed tomography (CT) is proposed. In order to serve as contrast‐enhanced agent, Ag nanoparticles (AgNPs) are composited on the surface of GO to promote its X‐ray absorption, and then simvastatin is coinjected for eliminating in vivo toxicity induced by AgNPs. It is found that GO/AgNPs can enhance the imaging of CT into the lung, liver, and kidney of mice for a long circulation time (≈24 h) and a safety profile in vivo in the presence of simvastatin. Interestingly, the lower dose of GO/AgNPs (≈0.5 mg per kg bw) shows an excellent performance for CT imaging of renal perfusion, and visually exhibits the right renal dysfunction in model mice. Hence, this work suggests that graphene nanoparticles will play a vital role for the future medical translational development including drug carrier, biosensing, and disease therapy.